Business
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
First patient treated in ongoing pivotal Phase 3 VIITAL™ study evaluating EB-101 for RDEB Additional patients dosed in the Phase 1/2 gene therapy studies for
About this update from Abeona Therapeutics Inc.
[{"type":"text","content":"First patient treated in ongoing pivotal Phase 3 VIITAL™ study evaluating EB-101 for RDEB Additional patients dosed in the Phase 1/2 gene therapy studies for MPS IIIA and MPS IIIB Positive interim data from MPS III gene therapy programs presented at WORLDSymposium™; updated results to be presented at ASGCT 2020 Appointed two industry leaders to Board of Directors and strengthened management team Company to host investor conference call Thursday, May 7, 2020 at 8:30 a.m. ET NEW YORK and CLEVELAND, May 06, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2020 financial results, which will be discussed on a conference call scheduled for Thursday, May 7, 2020 at 8:30 a.m. ET. Interested parties are invited to participate in the call by dialing 844-455-1352 (U.S. toll-free) or 509-844-0155 (international), and reference conference ID 5352629, or via webcast at https://investors.abeonatherapeutics.com/ir-calendar. “During these challenging times, our priority remains to ensure the safety of our employees and patients, while supporting continuity of our business and clinical operations,” said João Siffert, M.D., Chief Executive Officer of Abeona. “We have made considerable progress in our clinical programs in the first quarter of 2020, and are working with our investigators to minimize the impact of the COVID-19 pandemic. It is our intention to restore full patient access to our clinical programs as soon as possible. Our gene and cell therapies in development aim at addressing urgent unmet needs, and have the potential to provide durable benefit to patients who have no approved treatments.” First Quarter and Recent Highlights First patient treated in pivotal Phase 3 VIITAL™ study evaluating EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). An additional 10 patients have been prescreened for this study.Additional patients treated in dose cohort 3 of the Transpher A study and the Transpher B study.Presented positive interim data from the Transpher A study of ABO-102 at WORLDSymposium™ demonstrating improved neurocognitive skills 18 months to two years post-treatment in MPS IIIA patients younger than 30 months, sustained, dose-related biomarker improvements, and a favorable safety profile.Presented positive interim data from the ...